Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (2711)	8/1/1999 6:11:00 PM
From: out_of_the_loop	Respond to of 10293

Bp: The Tremacamra molecule is ICAM. Whether or not ICAM is the only thing that is in the local milieu is probably not significant in terms of viral infection if ICAM is indeed the receptor. I believe it is. Here is another reference that specifically states that: Cotran, RS, et. al., eds. Robbins Pathologic Basis of Disease, 6th Edition. 1999. WB Saunders (Phila, Toronto,etc) page 347. In addition, IgA will not be called if it is not a reinfection. If it is, the whole thing is moot because one is already immune. Interferon may be present but it will be a byproduct of the initial inflammatory response, so at first will have no significant role. Mass effect is but one reason I have a position in the stock. I believe it works and will find its way into the literature either in the NEJM or some place else decent. The recent publications of Tremacamra and the VPHM drug will make the Zicam study seem pretty timely. In addition, the p<0.001 of the Zicam study will be pretty compelling.